July 2011
Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p11
The article reports that Optimer's Dificid (fidaxomicin) tablets received approval to treat Clostridium difficile-associated diarrhea (CDAD).


Related Articles

  • Fidaxomicin (Dificid) for Clostridium difficile Infection. PATEL, DHIREN; GOLDMAN-LEVINE, JENNIFER D. // American Family Physician;2/1/2013, Vol. 87 Issue 3, p211 

    The article offers information on oral macrolide antibiotic Fidaxomicin used for the treatment of Clostridium difficile-associated diarrhea in adults. The drug is said to exhibit activity against species of clostridia, while having no or limited activity against normal gastrointestinal flora....

  • Cubist Pharmaceuticals to Move CDAD Candidate into Phase 3.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p50 

    The article focuses on the plan pf Cubist Pharmaceuticals Inc. to move CB-183,315, being experimented for the treatment of a life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea (CDAD), into a phase 3 trial in the U.S. It notes that positive...

  • Fecal Transplantation for the Treatment of Recurrent Clostridium Difficile Infection. Karadsheh, Zeid; Sule, Sachin // North American Journal of Medical Sciences;Jun2013, Vol. 5 Issue 6, p339 

    Clostridium difficile infection (CDI) is currently a leading cause of antibiotic and health care-related diarrhea. The incidence and the severity of CDI-related diarrhea have increased dramatically in the USA and Europe in the past few decades. The emergence of multidrug-resistant hypervirulent...

  • DIFICID.  // Monthly Prescribing Reference;Jul2011, Vol. 27 Issue 7, pA.8 

    A chapter of the book "Monthly Prescribing Reference" is presented. It presents a monograph on Dificid drug from Optimer Pharmaceuticals Inc. It mentions that the drug is used for the treatment of Clostridium difficile-associated diarrhea. Clinical trials reveal that fidaxomicin 200 milligram...

  • Fidaxomicin in the Treatment of Clostridium difficile-Associated Diarrhoea. Greig, James // Clinical Drug Investigation;2013, Vol. 33 Issue 1, p93 

    A response is presented to the article "Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price," by Sclar DA, Robison LM, Oganov AM, et al., with a focus on the price and usage of the antibiotic fidaxomicin for the treatment of...

  • JournalScan. Aithal, Guruprasad P. // Gut;Apr2010, Vol. 59 Issue 4, p20 

    An abstract of the article "JournalScan," by Guruprasad P. Aithal is presented.

  • The newest treatment strategy for Clostridium difficile: Worth a look? Boeser, Kimberly D. // Infectious Disease News;Jul2010, Vol. 23 Issue 7, p8 

    This article discusses a study on the effectiveness of oral vancomycin in the treatment of Clostridium difficile.

  • ERRATUM.  // Clinical Infectious Diseases;12/15/2011, Vol. 53 Issue 12, p1312 

    A correction to the article "Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections" published in the September 1 issue of the journal is presented.

  • Gastroenterology: A new treatment option for Clostridium difficile: Fecal transplantation.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article presents information on the fecal transplantation through colonoscopy which is regarded as a treatment of Clostridium difficile.


Read the Article


Sign out of this library

Other Topics